

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## SoftMedx Healthcare Limited

京玖醫療健康有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 648)**

### **UPDATE ON RESUMPTION**

Reference is made to the announcement of the Company dated 8 February 2023. Capitalised terms used in this announcement shall adopt the same meaning as those defined in the said announcement.

#### **UPDATE RESUMPTION PROGRESS**

On 21 April 2020, the Stock Exchange informed the Company that it would withhold exercising its right to delist the Company under Rule 6.01A(2)(b)(i) of the Listing Rules pending further development of the Company's submission to the Commission and may exercise its right under Rule 6.01A of the Listing Rules at a later stage when it considers appropriate. On 1 December 2020 and 6 May 2021, the Company was informed by the Stock Exchange that the Company is required to demonstrate compliance with Rule 13.24 and Rules 3.10(1) and 3.21 of the Listing Rules as additional Resumption Conditions respectively. The Stock Exchange may modify the Resumption Conditions and/or give further guidance if the Company's situation changes. The Company will continue to take steps to address the concerns of the Commission and the Stock Exchange.

#### **UPDATE ON BUSINESS OPERATION**

The Company has continued to engage in the healthcare business and will review and make adjustment to its business portfolio and development plans as appropriate from time to time.

## **UPDATE ON LITIGATION**

As disclosed in the announcement dated 24 April 2023, a winding up petition was filed by China Jianxin Credit Services Limited, a creditor, against the Company in the High Court of Hong Kong on 18 April 2023 for the alleged failure of the Company to settle its claim of HK\$16,175,304, together with the unpaid interest and cost thereon. The Company is seeking legal advice in respect of the petition and will keep its shareholders and potential investors informed of any further significant development as and when appropriate in accordance with the Listing Rules.

## **GENERAL**

Trading in the shares of the Company will continue to be suspended pending fulfilment of the Resumption Conditions. The Company will keep its shareholders and potential investors posted of any material development in this regard as and when appropriate.

**Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.**

For and on behalf of the board of  
**SoftMedx Healthcare Limited**  
**Lam Sung Him Gaston**  
*Company Secretary*

Hong Kong, 28 April 2023

*As at the date of this announcement, the board of directors of the Company comprises Mr. Chan Ka Chung, Mr. Cheung Wai Kwan and Mr. Wang Jianguo as executive directors; and Ms. Hu Xuezheng, Mr. Lin Pinzhuo and Mr. Yiu Chun Wing as independent non-executive directors.*